AU767193B2 - Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B - Google Patents
Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B Download PDFInfo
- Publication number
- AU767193B2 AU767193B2 AU31095/99A AU3109599A AU767193B2 AU 767193 B2 AU767193 B2 AU 767193B2 AU 31095/99 A AU31095/99 A AU 31095/99A AU 3109599 A AU3109599 A AU 3109599A AU 767193 B2 AU767193 B2 AU 767193B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- vaccine
- gene
- rsv
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000712079 Measles morbillivirus Species 0.000 title claims description 147
- 230000035772 mutation Effects 0.000 title claims description 92
- 241000711920 Human orthopneumovirus Species 0.000 title claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 159
- 125000003729 nucleotide group Chemical group 0.000 claims description 157
- 241000700605 Viruses Species 0.000 claims description 147
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 136
- 108090000623 proteins and genes Proteins 0.000 claims description 134
- 229960005486 vaccine Drugs 0.000 claims description 115
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 235000018102 proteins Nutrition 0.000 claims description 61
- 230000035897 transcription Effects 0.000 claims description 61
- 238000013518 transcription Methods 0.000 claims description 61
- 230000002238 attenuated effect Effects 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 235000001014 amino acid Nutrition 0.000 claims description 43
- 229940024606 amino acid Drugs 0.000 claims description 42
- 208000015181 infectious disease Diseases 0.000 claims description 34
- 230000010076 replication Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000002458 infectious effect Effects 0.000 claims description 20
- 229910052698 phosphorus Inorganic materials 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 239000004473 Threonine Substances 0.000 claims description 13
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 12
- 101150111062 C gene Proteins 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 5
- 108010062796 arginyllysine Proteins 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 64
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 62
- 108020004999 messenger RNA Proteins 0.000 description 42
- 230000003612 virological effect Effects 0.000 description 38
- 241000282326 Felis catus Species 0.000 description 26
- 201000005505 Measles Diseases 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 18
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 18
- 101150062031 L gene Proteins 0.000 description 17
- 101150107578 SH gene Proteins 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 210000002845 virion Anatomy 0.000 description 15
- 101710141454 Nucleoprotein Proteins 0.000 description 14
- 241000711902 Pneumovirus Species 0.000 description 14
- 230000014616 translation Effects 0.000 description 14
- 108010083644 Ribonucleases Proteins 0.000 description 13
- 102000006382 Ribonucleases Human genes 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 241001493065 dsRNA viruses Species 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 101710181008 P protein Proteins 0.000 description 11
- 101710177166 Phosphoprotein Proteins 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 101150084044 P gene Proteins 0.000 description 10
- 102100034574 P protein Human genes 0.000 description 10
- 210000003501 vero cell Anatomy 0.000 description 10
- 241000712083 Canine morbillivirus Species 0.000 description 9
- 241000711513 Mononegavirales Species 0.000 description 9
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 9
- 238000000636 Northern blotting Methods 0.000 description 9
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 8
- 241000711502 Paramyxovirinae Species 0.000 description 8
- 241000711975 Vesicular stomatitis virus Species 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 241000711408 Murine respirovirus Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 230000005030 transcription termination Effects 0.000 description 6
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 101150034814 F gene Proteins 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 241001533467 Rubulavirus Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 208000030500 lower respiratory tract disease Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 241000557626 Corvus corax Species 0.000 description 4
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 4
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 101710128560 Initiator protein NS1 Proteins 0.000 description 4
- 101150046652 M2 gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000712045 Morbillivirus Species 0.000 description 4
- 101710144127 Non-structural protein 1 Proteins 0.000 description 4
- 101710144128 Non-structural protein 2 Proteins 0.000 description 4
- 101710199667 Nuclear export protein Proteins 0.000 description 4
- 241000711504 Paramyxoviridae Species 0.000 description 4
- 241000711904 Pneumoviridae Species 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- 102000004389 Ribonucleoproteins Human genes 0.000 description 4
- 108010081734 Ribonucleoproteins Proteins 0.000 description 4
- 241000711897 Rinderpest morbillivirus Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 241000144290 Sigmodon hispidus Species 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 3
- 101710117545 C protein Proteins 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091062157 Cis-regulatory element Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 description 3
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 3
- 101710085938 Matrix protein Proteins 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 3
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 3
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 3
- 229940124679 RSV vaccine Drugs 0.000 description 3
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005029 transcription elongation Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 101100242563 Legionella pneumophila pal gene Proteins 0.000 description 2
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 229940124862 Measles virus vaccine Drugs 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000711899 Phocine morbillivirus Species 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 101100209986 Rattus norvegicus Slc18a1 gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- LCPVBXOHXMBLFW-JSGCOSHPSA-N Trp-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)=CNC2=C1 LCPVBXOHXMBLFW-JSGCOSHPSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 101150118163 h gene Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 101150061325 mv gene Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001944 turbinate Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
- 241000712462 Bovine ephemeral fever virus Species 0.000 description 1
- 241000711895 Bovine orthopneumovirus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241001502545 Dolphin morbillivirus Species 0.000 description 1
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101100001154 Escherichia coli aggC gene Proteins 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711941 Murine orthopneumovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 101710132653 Protein M2 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 108010046983 Ribonuclease T1 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 101710200413 Small hydrophobic protein Proteins 0.000 description 1
- 241001428894 Small ruminant morbillivirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LUMXICQAOKVQOB-YWIQKCBGSA-N Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O LUMXICQAOKVQOB-YWIQKCBGSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 101710165741 Virion-associated protein Proteins 0.000 description 1
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
- 241000701815 Xipapillomavirus 1 Species 0.000 description 1
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- -1 amino acids sodium glutamate Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 102220351054 c.122G>A Human genes 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003213 live attenuated measles Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 244000309458 single stranded enveloped RNA virus Species 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7946698P | 1998-03-26 | 1998-03-26 | |
| US60/079466 | 1998-03-26 | ||
| PCT/US1999/006225 WO1999049017A2 (en) | 1998-03-26 | 1999-03-22 | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3109599A AU3109599A (en) | 1999-10-18 |
| AU767193B2 true AU767193B2 (en) | 2003-11-06 |
Family
ID=22150746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31095/99A Ceased AU767193B2 (en) | 1998-03-26 | 1999-03-22 | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1064358A2 (de) |
| JP (1) | JP2002507408A (de) |
| KR (1) | KR20010080863A (de) |
| CN (2) | CN1600852A (de) |
| AU (1) | AU767193B2 (de) |
| BR (1) | BR9909076A (de) |
| CA (1) | CA2323927A1 (de) |
| IL (1) | IL138681A0 (de) |
| WO (1) | WO1999049017A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE343589T1 (de) * | 2000-06-23 | 2006-11-15 | Wyeth Corp | Modofiziertes morbillivirus v proteine |
| DK1375512T3 (da) * | 2002-06-20 | 2009-10-26 | Pasteur Institut | Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger |
| EP1613345B1 (de) * | 2003-03-28 | 2010-05-26 | MedImmune, LLC | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 |
| JPWO2008065752A1 (ja) * | 2006-11-30 | 2010-03-04 | 国立大学法人北海道大学 | ｄｉＲＮＡを有効成分とする免疫治療用薬剤 |
| US9011876B2 (en) | 2008-11-05 | 2015-04-21 | Merck Sharp & Dohme Corp. | Live, attenuated respiratory syncytial virus |
| EP2420242A1 (de) | 2010-08-20 | 2012-02-22 | Lauer, Ulrich M. | Onkolytisches Masernvirus |
| JP6453063B2 (ja) * | 2014-12-02 | 2019-01-16 | 国立大学法人北海道大学 | アジュバント組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3045581B2 (ja) * | 1991-10-14 | 2000-05-29 | 社団法人北里研究所 | 麻疹ワクチンウイルス株同定方法 |
| TW275632B (de) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co | |
| CA2265554A1 (en) * | 1996-09-27 | 1998-04-02 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
-
1999
- 1999-03-22 CA CA002323927A patent/CA2323927A1/en not_active Abandoned
- 1999-03-22 BR BR9909076-7A patent/BR9909076A/pt not_active IP Right Cessation
- 1999-03-22 IL IL13868199A patent/IL138681A0/xx unknown
- 1999-03-22 EP EP99912799A patent/EP1064358A2/de not_active Withdrawn
- 1999-03-22 KR KR1020007010624A patent/KR20010080863A/ko not_active Ceased
- 1999-03-22 CN CNA2004100685486A patent/CN1600852A/zh active Pending
- 1999-03-22 WO PCT/US1999/006225 patent/WO1999049017A2/en not_active Ceased
- 1999-03-22 CN CNB998043826A patent/CN1177927C/zh not_active Expired - Fee Related
- 1999-03-22 JP JP2000537978A patent/JP2002507408A/ja active Pending
- 1999-03-22 AU AU31095/99A patent/AU767193B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1600852A (zh) | 2005-03-30 |
| BR9909076A (pt) | 2000-12-05 |
| JP2002507408A (ja) | 2002-03-12 |
| WO1999049017A2 (en) | 1999-09-30 |
| KR20010080863A (ko) | 2001-08-25 |
| CA2323927A1 (en) | 1999-09-30 |
| AU3109599A (en) | 1999-10-18 |
| CN1177927C (zh) | 2004-12-01 |
| WO1999049017A3 (en) | 1999-12-16 |
| IL138681A0 (en) | 2001-10-31 |
| CN1294628A (zh) | 2001-05-09 |
| EP1064358A2 (de) | 2001-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4427897A (en) | 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales | |
| CA2302867A1 (en) | Attenuated respiratory syncytial viruses | |
| CN101012454B (zh) | 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法 | |
| AU2020203460B2 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
| CA2304932C (en) | Recombinant rsv virus expression systems and vaccines | |
| KR20110063863A (ko) | 생 약독화 호흡기 세포융합 바이러스 | |
| US6830748B1 (en) | Recombinant RSV virus expression systems and vaccines | |
| AU767193B2 (en) | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B | |
| US20120308602A1 (en) | Recombinant RSV Virus Expression Systems And Vaccines | |
| EP1480671A2 (de) | Rekombinante rsv-virus-expressionssysteme und -impfstoffe | |
| AU2002236522A1 (en) | Recombinant RSV virus expression systems and vaccines | |
| AU2016366771B2 (en) | Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes | |
| MXPA00009256A (en) | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b | |
| KR20230021115A (ko) | 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus) | |
| AU8933001A (en) | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales | |
| AU5592201A (en) | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences | |
| AU5591601A (en) | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: WYETH HOLDINGS CORPORATION Free format text: FORMER NAME: AMERICAN CYANAMID COMPANY |
|
| FGA | Letters patent sealed or granted (standard patent) |